1,240,000 Shares in Sera Prognostics, Inc. $SERA Acquired by Aberdeen Group plc

Key Points

• Aberdeen Group plc has invested approximately $4.56 million in Sera Prognostics, acquiring 1,240,000 shares, which represents 3.29% of the company.
• CEO Zhenya Lindgardt sold 23,042 shares at an average price of $1.43, resulting in a decrease in their ownership by 2.66% and leaving them with 844,209 shares valued at about $1.2 million.
• Sera Prognostics reported a quarterly EPS of ($0.16), which exceeded the consensus estimate of ($0.21), but the company still faces a negative net margin of 30,306.48%.

Aberdeen Group plc acquired a new stake in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,240,000 shares of the company's stock, valued at approximately $4,563,000. Aberdeen Group plc owned 3.29% of Sera Prognostics as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Sera Prognostics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 599,702 shares of the company's stock valued at $4,883,000 after purchasing an additional 12,865 shares during the period. AWM Investment Company Inc. boosted its holdings in Sera Prognostics by 12.2% in the 4th quarter. AWM Investment Company Inc. now owns 585,134 shares of the company's stock valued at $4,763,000 after purchasing an additional 63,820 shares during the period. Captrust Financial Advisors boosted its holdings in Sera Prognostics by 2.2% in the 4th quarter. Captrust Financial Advisors now owns 487,894 shares of the company's stock valued at $3,971,000 after purchasing an additional 10,673 shares during the period. Northern Trust Corp boosted its holdings in Sera Prognostics by 11.8% in the 4th quarter. Northern Trust Corp now owns 272,860 shares of the company's stock valued at $2,221,000 after purchasing an additional 28,863 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Sera Prognostics in the 4th quarter valued at about $1,285,000. Institutional investors own 54.64% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Sera Prognostics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

Insider Transactions at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 23,042 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $1.43, for a total transaction of $32,950.06. Following the completion of the transaction, the chief executive officer directly owned 844,209 shares in the company, valued at $1,207,218.87. This represents a 2.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 44,014 shares of company stock worth $68,588. 15.80% of the stock is owned by corporate insiders.

Sera Prognostics Stock Up 15.5%

Shares of NASDAQ:SERA traded up $0.41 during midday trading on Tuesday, hitting $3.05. The stock had a trading volume of 413,190 shares, compared to its average volume of 105,235. The company's 50-day moving average price is $2.59 and its 200-day moving average price is $2.94. The company has a market capitalization of $114.89 million, a P/E ratio of -3.59 and a beta of 0.99. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. Research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.